IL-10 Gene Variants and Hepatitis B Treatment Response
Author Information
Author(s): Wang Shaoyang, Huang Dedong, Sun Shunlai, Ma Weimin, Zhen Qin
Primary Institution: Department of infectious diseases, the Fuzhou General Hospital, Fu Zhou, Fujian Province, China
Hypothesis
Variation in interleukin-10 promoter polymorphism would predict the likelihood of sustained response of chronic hepatitis B to treatment with interferon alfa.
Conclusion
The study found that certain IL-10 gene variants are associated with a better initial response to interferon alfa therapy in chronic hepatitis B patients.
Supporting Evidence
- The -592A allele and -819T allele were more frequent in sustained responders compared to non-responders.
- Homozygosity for the -592A/A and -819T/T genotypes was strongly associated with sustained response.
- The study included a control group of 48 healthy volunteers for comparison.
Takeaway
Some people with chronic hepatitis B have genes that help them respond better to a specific treatment, which can help them get better.
Methodology
The study analyzed IL-10 gene polymorphisms in 52 chronic hepatitis B patients using PCR and compared responders to non-responders.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study was retrospective and limited to a specific population, which may affect the generalizability of the findings.
Participant Demographics
52 Chinese Han patients, with 28 non-responders and 24 sustained responders, predominantly male.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website